UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 10, 2013 (October 10, 2013)
GUIDED THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 0-22179 | 58-2029543 |
(State or Other Jurisdiction of | (Commission File Number) | (IRS Employer Identification No.) |
Incorporation) |
Registrant’s telephone number, including area code: (770) 242-8723
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
| |
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
| |
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
| |
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 7.01 (Regulation FD Disclosure)
On October 10, 2013, the registrant publicly issued a press release announcing that the registrant has signed agreements for distributors to market the LuViva® Advanced Cervical Scan in additional countries, as more fully described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which information is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Number | Exhibit |
99.1 | Press Release dated October 10, 2013 |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GUIDED THERAPEUTICS, INC. | |
/s/ Mark L. Faupel, Ph.D. | |
By: Mark L. Faupel, Ph.D. | |
CEO & President | |
Date: October 10, 2013 |
3 |